Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors

Background Dacomitinib (PF-00299804) is an oral, irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases. Methods This phase I, open-label, dose-escalation study (clinicaltrials.gov: NCT00783328) primarily evaluated the safety and tolerability...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Takahashi, Toshiaki, Boku, Narikazu, Murakami, Haruyasu, Naito, Tateaki, Tsuya, Asuka, Nakamura, Yukiko, Ono, Akira, Machida, Nozomu, Yamazaki, Kentaro, Watanabe, Junichiro, Ruiz-Garcia, Ana, Imai, Keiji, Ohki, Emiko, Yamamoto, Nobuyuki
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer US 2012
Schlagworte:
Phase I Studies
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3523469/
https://ncbi.nlm.nih.gov/pubmed/22249430
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-011-9789-z
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge